Previous 10 | Next 10 |
Vir Biotechnology's (VIR) Q4 2020 results missed analyst expectations on both EPS and revenue.Revenues rose to $1.7M from $1M in the prior-year period.The company's net loss widened to $105.6M from $63.8M.R&D expenses rose to $87.1M compared to $52.9M in Q4 2019.In the pipeline, Vir says ...
Vir Biotechnology (VIR): Q4 GAAP EPS of -$0.83 misses by $0.11.Revenue of $1.73M (+76.5% Y/Y) misses by $3.08M.As of Dec. 31, 2020, excluding restricted cash, the Company had ~$736.9M in cash, cash equivalents and investments.Shares -2.67%.Press Release For further details see: Vir Biot...
SAN FRANCISCO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2020. “Vir closed 2020 delivering strong progress across our entire de...
Looking For The Best Health Care Stocks To Watch Right Now? You can’t deny that health care stocks have been in the limelight as of late. Throughout this near-year-long pandemic, the general public has and continues to hear about the importance of health. For investors, t...
Vir Biotechnology (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) have gone from dating to a full-blown relationship in under a year. Could a marriage be next? Last April, the duo hooked up to develop antibody treatments and preventive options for COVID-19. As part of ...
Shares of Vir Biotechnology (NASDAQ: VIR) were 12.6% higher as of 12:47 p.m. EST on Wednesday. The big gain came after Vir and GlaxoSmithKline (NYSE: GSK) announced that they're expanding their collaboration to include the development of therapies targeting influenza and oth...
Comstock Mining (LODE) +285% after buying stake in lithium-ion battery recycler.TDH Holdings (PETZ) +248%.Dogness (International) (DOGZ) +110%.Oncolytics Biotech (ONCY) +54%.ZW Data Action Technologies (CNET) +42%.China Xiangtai Food (PLIN) +41%.AirNet Technology (ANTE) +34%.Aqua Metals ...
Vir Biotechnology (VIR) jumps 12% premarket after signing a binding agreement with GlaxoSmithKline (GSK) to expand their existing collaboration to include the R&D of new therapies for influenza and other respiratory viruses. The expanded deal provides GSK exclusive rights to ...
– Companies applying their combined expertise in immunology and infectious diseases to accelerate the development of promising monoclonal antibody candidates for influenza – – Functional genomics collaboration expanded to include respiratory viruses, Vir’s ...
SAN FRANCISCO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021. The update will ...
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology Inc. Company Name:
VIR Stock Symbol:
NASDAQ Market:
Vir Biotechnology Inc. Website:
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will ...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
2024-07-08 10:47:03 ET BITX (BITX) BITX is trading DOWN for the last 4 days, and it at trading at $27.48 with volume of 3,908,355 and a one day change of $-0.37 (-1.33%). BITX has a 52-week low of 0.00 and a 52-week high of $0.00. The business's 50-day moving average price is $45.40...